audit on the use of oral baclofen in children with cerebral palsy attending warrington cdc l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
AUDIT ON THE USE OF ORAL BACLOFEN IN CHILDREN WITH CEREBRAL PALSY ATTENDING WARRINGTON CDC PowerPoint Presentation
Download Presentation
AUDIT ON THE USE OF ORAL BACLOFEN IN CHILDREN WITH CEREBRAL PALSY ATTENDING WARRINGTON CDC

Loading in 2 Seconds...

play fullscreen
1 / 19

AUDIT ON THE USE OF ORAL BACLOFEN IN CHILDREN WITH CEREBRAL PALSY ATTENDING WARRINGTON CDC - PowerPoint PPT Presentation


  • 170 Views
  • Uploaded on

AUDIT ON THE USE OF ORAL BACLOFEN IN CHILDREN WITH CEREBRAL PALSY ATTENDING WARRINGTON CDC. Dr B George. Aim. To identify various factors affecting usage. To identify existing regimes of prescription. To document benefits and side effects.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'AUDIT ON THE USE OF ORAL BACLOFEN IN CHILDREN WITH CEREBRAL PALSY ATTENDING WARRINGTON CDC' - finn


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
audit on the use of oral baclofen in children with cerebral palsy attending warrington cdc

AUDIT ON THE USE OF ORAL BACLOFEN IN CHILDREN WITH CEREBRAL PALSY ATTENDING WARRINGTON CDC

Dr B George

slide2
Aim
  • To identify various factors affecting usage.
  • To identify existing regimes of prescription.
  • To document benefits and side effects.
  • To identify existing or prevalent guidelines on oral prescription.
methods
Methods
  • List of all children registered as ICD-10 (G80-83) codes as having cerebral palsy under the Warrington CDC. Obtained from IT (medical records) at Warrington CSU.
  • Notes retrieved and children currently or previously on Baclofen identified.
  • Data collated on above sub-set.
slide4

Total children registered with CP 78

  • Total notes obtained 43
  • Children with CP on analysis 42
  • Children currently on Baclofen 09
  • Children previously on Baclofen 02
slide5

‘n’ total no 11

  • % of children with CP on

Baclofen is 11/42 = 26.2%

  • Avg age of our sub group 10y 1m
  • Avg age at diagnoses 30 m
  • Males 8
  • Females 3
body pattern involvement
Body pattern involvement
  • Diplegia 3
  • Quad/tetraplegia 3
  • Hemiparesis/plegia 1
  • Undiagnosed syndrome 2
  • CP -unspecified 2
etiology
Etiology
  • Asphyxia 8
  • Syndrome (Undiagnosed) 2
  • Unspecified 1
movt problems
Movt problems
  • Spasticity 10
  • Dystonia 1
therapies
Therapies
  • Physiotherapy
  • Occupational therapy
  • Speech & language
baclofen data
Baclofen – data

Freq

  • ODS 1
  • BDS 3
  • TDS 6
  • QDS 1
slide13
BNF
  • BNF advises 0.75 mg – 2 mg/kg daily or 2.5 mg q.d.s increased gradually to maintainence.
  • Child 1–2 years 10–20 mg daily in divided doses, Child 2–6 years 20–30 mg daily in divided doses, Child 6–10 years 30–60 mg daily in divided doses
  • Child 10–18 years 5 mg 3 times daily increased gradually; max. 2.5 mg/kg or 100 mg daily
slide15
BNF
  • BNF advises 0.75 mg – 2 mg/kg daily or 2.5 mg q.d.s increased gradually to maintainence.
  • Child 1–2 years 10–20 mg daily in divided doses, Child 2–6 years 20–30 mg daily in divided doses, Child 6–10 years 30–60 mg daily in divided doses
  • Child 10–18 years 5 mg 3 times daily increased gradually; max. 2.5 mg/kg or 100 mg daily
side effects
Side effects
  • Nil 7
  • KK- stopped as no response(no s.e.)
  • MW - stopped as worsening reflux
  • DM – vomiting,
  • JC -- decreased appetite
  • VR-Increasing spasticity, stopped walking unaided, swallowing diff---dose reduced
conclusions
Conclusions
  • All patients prescribed for increasing hypertonia.
  • No standardised regime of prescription identified-i.e. starting regime, increasing dosage, frequency.
  • All mg/kg dosages were within BNF limits.
  • Some side-effects noted, mainly increasing feeding problems and reflux. ?statistical significance due to small numbers.
  • No guidelines identified in literature search specifically for oral Baclofen prescription.
recommendations
RECOMMENDATIONS
  • To propose a regional standardised regime for prescription.
  • To generate information/advice sheet on Baclofen for prescribers in the hospitals and community.
  • To generate clinic sheet for prescribers to document information on Baclofen on the first and then on each clinic visit.